Introduction: The purpose of this study was to measure the structures of the ventral of lateral masses using cadaver specimens and to quantitatively compare the safety zone for the two major techniques used on each vertebral level from C3 to C6.
Methods: This study is based on 52 cervical vertebrae of 13 cadavers. The anatomical measurements focused on the anterior surface of the lateral mass. We investigated the safety width, heights, and the height of nerve roots.
Results: The mean values of the safety width of the Magerl technique from C3 to C6 were 6.1, 7.3, 6.4 and 4.3 mm, respectively. The mean values of the safety width of the Roy-Camille technique were 6.7, 6.6, 5.8 and 5.4 mm, respectively. The mean values of the safety height of the Magerl technique were 5.0, 5.4, 5.8 and 5.2 mm, respectively. The mean values of the safety height of the Roy-Camille technique were 4.9, 4.0, 1.0 and -1.2 mm, respectively. The mean values of the nerve root height were 3.9, 4.9, 5.9 and 6.9 mm, respectively.
Conclusion: The safety width of the Magerl technique was shorter at C6 because the vertebral artery runs more laterally at C6. The height for the Magerl technique was not significantly different from C3 to C6, however, the safety height for the Roy-Camille technique was significantly shorter at C5 and C6. Our findings suggest that it is important to ensure that the screw(s) penetrate through the cranial side of the ventral aspect of a lateral mass when performing the Magerl technique at all vertebral levels, and to carefully select the screw length when using the Roy-Camille technique, especially at C5 and C6, in order to avoid nerve root injury.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265595 | PMC |
http://dx.doi.org/10.1007/s00586-011-1984-2 | DOI Listing |
J Allergy Clin Immunol Pract
December 2024
EUCAN Medical Affairs, Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zürich), Switzerland.
Background: Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of cutaneous or subcutaneous edema. There is clinical need for treatments that reduce the rate of HAE attacks in patients.
Objectives: Primary objectives were to evaluate the effectiveness of lanadelumab on attack free rate (AFR; proportion of patients who had zero HAE attacks), and on every two weeks (Q2W) and every four weeks (Q4W) adjustments on AFR.
J Allergy Clin Immunol Pract
December 2024
Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Insititute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
Background: Mastocytosis is characterized by expanding neoplastic mast cells in organs such as the skin, bone marrow, and gastrointestinal tract. The release of mast cell mediators triggers cutaneous, gastrointestinal, and other symptoms. Currently, no validated mastocytosis-specific patient-reported outcome measure (PROM) exists to assess disease control.
View Article and Find Full Text PDFEur J Pediatr Surg
December 2024
Department of Pediatric Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, Germany.
Introduction: Interferential current (IFC) has been studied in several clinical trials for the treatment of bowel motility disorders, most often in children. However, only moderate effects are reported, and in contrast to IFC, the so-called placebo application is indiscernible. The mechanisms and neuroanatomic points of action remain elusive.
View Article and Find Full Text PDFN Engl J Med
October 2024
From Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam (D.M.C., R.S.P); Cambridge University Hospitals, NHS Foundation Trust, Cambridge, United Kingdom (P.G.); the Institute of Allergology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, and Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin (M.M.), and the Department of Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt (E.A.-P.) - all in Germany; the Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney (C.H.K.); University of Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000, INSERM, and the Department of Internal Medicine and Clinical Immunology, CHU Lille, National Reference Center for Angioedema (CREAK), Lille (D.L.), and CREAK, Angioedema Center of Reference and Excellence (ACARE), Grenoble Alpes University Hospital, and the Translational Research in Autoimmunity and Inflammation Arm (T-RAIG), French National Center for Scientific Research (CNRS), Grenoble (L.B.) - all in France; Intellia Therapeutics, Cambridge, MA (D.M., J.S.B., M.Y.S., A.G., Y.X., A.M.A., D.L.); and the Department of Immunology, Auckland City Hospital, and the Department of Medicine, University of Auckland - both in Auckland, New Zealand (K.L., H.J.L.).
Background: Hereditary angioedema is a rare genetic disease characterized by severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 ().
View Article and Find Full Text PDFAllergy
October 2024
Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!